We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)
Read MoreHide Full Article
Horizon Pharma plc is scheduled to report third-quarter 2017 results before the opening bell on Nov 6.
Last quarter, the company missed expectations by 16%. Let’s see how things are shaping up for this quarter.
Horizon Pharma’s shares have declined 12% in the year so far, underperforming the industry’s gain of 0.9%.
Factors Likely to Impact This Quarter
Concurrent with the second-quarter earnings, the company raised its outlook for 2017 and now expects sales in the range of $1.010-$1.045 billion, compared to the earlier estimate of $985-$1.020 billion.
Horizon Pharma is significantly increasing investments in one of its key growth drivers, Krystexxa, and projects peak sales of around $400 million in 2017 driven by higher demand. The guidance includes assumption of lower net average net realized price from the U.S. Government's Health Resource and Services Administration's Final Rule on 340B drug ceiling price implementation scheduled for Oct 1.
The company expects continued double-digit net sales growth for Ravicti in 2017, with room for additional uptake due to the recent label expansion. The drug is also expected to be launched in Europe in the second half. However, sales of Procysbi will decline due to the divestiture of European rights. Sales of Actimmune are projected to grow in low single-digits driven by a year-over-year growth in the second half.
Meanwhile, Horizon Pharma’s primary care business is under pressure due to the implementation of a new commercial model, where the company is teaming up with pharmacy benefit managers and payers to help patients obtain access to its medicines.
During the third-quarter earnings call, focus will be on the performance of the business units, along with that of products like Actimmune and Krystexxa.
Earnings Whispers
Our proven model does not conclusively show that Horizon Pharma is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -8.48%. This is because both the Most Accurate estimate is 21 cents while the Zacks Consensus Estimate is currently pegged at 22 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter..
Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). As it is, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The company is expected to release third-quarter results on Nov 7.
Mylan N.V. has an Earnings ESP of +3.9% and currently carries a Zacks Rank #2. The company is expected to release third-quarter results on Nov 6.
(NOTE: We are republishing this article to correct a mistake. The original version, published earlier today, Thursday, November 2, 2017, should no longer be relied upon.)
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)
Horizon Pharma plc is scheduled to report third-quarter 2017 results before the opening bell on Nov 6.
Last quarter, the company missed expectations by 16%. Let’s see how things are shaping up for this quarter.
Horizon Pharma’s shares have declined 12% in the year so far, underperforming the industry’s gain of 0.9%.
Factors Likely to Impact This Quarter
Concurrent with the second-quarter earnings, the company raised its outlook for 2017 and now expects sales in the range of $1.010-$1.045 billion, compared to the earlier estimate of $985-$1.020 billion.
Horizon Pharma is significantly increasing investments in one of its key growth drivers, Krystexxa, and projects peak sales of around $400 million in 2017 driven by higher demand. The guidance includes assumption of lower net average net realized price from the U.S. Government's Health Resource and Services Administration's Final Rule on 340B drug ceiling price implementation scheduled for Oct 1.
The company expects continued double-digit net sales growth for Ravicti in 2017, with room for additional uptake due to the recent label expansion. The drug is also expected to be launched in Europe in the second half. However, sales of Procysbi will decline due to the divestiture of European rights. Sales of Actimmune are projected to grow in low single-digits driven by a year-over-year growth in the second half.
Meanwhile, Horizon Pharma’s primary care business is under pressure due to the implementation of a new commercial model, where the company is teaming up with pharmacy benefit managers and payers to help patients obtain access to its medicines.
During the third-quarter earnings call, focus will be on the performance of the business units, along with that of products like Actimmune and Krystexxa.
Earnings Whispers
Our proven model does not conclusively show that Horizon Pharma is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -8.48%. This is because both the Most Accurate estimate is 21 cents while the Zacks Consensus Estimate is currently pegged at 22 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter..
Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). As it is, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Horizon Pharma PLC Price and EPS Surprise
Horizon Pharma PLC Price and EPS Surprise | Horizon Pharma PLC Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Agenus Inc. (AGEN - Free Report) has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 7. You can see the complete list of today’s Zacks #1 Rank stocks here.
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The company is expected to release third-quarter results on Nov 7.
Mylan N.V. has an Earnings ESP of +3.9% and currently carries a Zacks Rank #2. The company is expected to release third-quarter results on Nov 6.
(NOTE: We are republishing this article to correct a mistake. The original version, published earlier today, Thursday, November 2, 2017, should no longer be relied upon.)
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>